OncoMatch/Clinical Trials/NCT06427447
Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
Is NCT06427447 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Adjuvant chemoradiotherapy and Adjuvant chemotherapy for pancreatic cancer.
Treatment: Adjuvant chemoradiotherapy · Adjuvant chemotherapy — In this trial, we aim to compare the outcomes of adjuvant chemoradiotherapy with chemotherapy for patients with resected pancreatic cancer who are at high risk of disease progressions.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any cancer treatment after surgical resection
No history of cancer treatment after surgical resection
Lab requirements
Blood counts
White blood cell count ≥4.0×10^9/L, neutrophil count ≥2.0×10^9, hemoglobin level ≥100g/L, platelet count ≥100×10^9/L
Kidney function
creatinine level within the normal
Liver function
ALT and AST level < 2.5 times the upper limit of normal, total bilirubin level within the normal
No abnormality in blood routine test, liver and kidney function test and coagulation test (White blood cell count ≥4.0×10^9/L, neutrophil count ≥2.0×10^9, hemoglobin level ≥100g/L, platelet count ≥100×10^9/L, ALT and AST level < 2.5 times the upper limit of normal, total bilirubin and creatinine level within the normal, international normalized ratio <2)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify